Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Stabilization and escalation
Airway and breathing compromise
If altered mental status or impending respiratory failure, escalate to resuscitation bay
If SpO2 < 92% or increased work of breathing, supplemental oxygen and ventilation support
Circulatory shock and sepsis
If SBP < 90 mmHg or MAP < 65 mmHg, initiate sepsis pathway
If lactate ≥ 2 mmol/L, sepsis physiology and perfusion reassessment trigger
If lactate ≥ 4 mmol/L or vasopressor requirement, ICU-level care trigger
Time-critical consult triggers
If peritonitis or suspected perforation, immediate surgical consult
If cholangitis suspected, urgent GI and surgery coordination for biliary decompression
If emphysematous cholecystitis suspected, emergent surgery trigger
Key decision points
Diagnostic framing
Acute cholecystitis syndrome
RUQ pain with systemic inflammation and supportive imaging
Complicated disease suspicion with organ dysfunction or severe local inflammation
Alternate biliary syndromes
Biliary colic without systemic inflammation
Choledocholithiasis pattern with cholestatic labs and jaundice
Acute cholangitis pattern with fever and jaundice plus systemic toxicity
Monitoring targets
Monitoring and targets
Hemodynamics
MAP ≥ 65 mmHg
Urine output ≥ 0.5 mL/kg/hour
Pain and nausea control
Analgesia response within 30-60 minutes
Emesis control to enable oral meds when appropriate
History
Presenting features
Symptom pattern
RUQ or epigastric pain
Duration > 6 hours
Postprandial fatty food association
Radiation to right shoulder or back
Nausea or vomiting
Fever or rigors
Risk context
Predisposing factors
Gallstones history
Prior biliary colic episodes
Prior ultrasound cholelithiasis
Pregnancy or postpartum state
Rapid weight loss or bariatric surgery
Hemolytic disorders
Critical illness risk for acalculous disease
Red flags and complications
Complication clues
Jaundice or dark urine
Choledocholithiasis or cholangitis concern
Persistent hypotension
Sepsis concern
Diffuse abdominal pain
Peritonitis or perforation concern
Confusion or lethargy
Sepsis or organ dysfunction concern
Medication and comorbidity modifiers
Modifiers
Anticoagulant or antiplatelet therapy
Diabetes mellitus
Immunosuppression
Chronic kidney disease
Prior abdominal surgery
Physical Exam
General and vitals
Physiologic severity
Fever
Temperature ≥ 38.0 C supports systemic inflammation
Tachycardia
Hypotension
Tachypnea
Abdominal exam
RUQ findings
RUQ tenderness
Guarding
Rebound tenderness
Murphy sign
Inspiratory arrest with RUQ palpation
Palpable gallbladder mass
System review for complications
Complication signs
Jaundice
Scleral icterus
Peritonitis
Diffuse guarding
Rigidity
Sepsis
Altered mental status
Poor perfusion
PITFALLS
Diagnostic pitfalls
Older adults with minimal fever or pain despite severe disease
Diabetics with blunted inflammatory response
Acalculous cholecystitis in critically ill with subtle abdominal findings
Differential Diagnosis
Life-threatening alternatives
High-risk diagnoses
Acute cholangitis (ICD-10 K83.0)
Fever plus jaundice plus RUQ pain pattern
Acute pancreatitis (ICD-10 K85.x)
Epigastric pain radiating to back
Perforated viscus (ICD-10 K63.1 or K25.1 etc)
Sudden severe pain with peritonitis
Mesenteric ischemia (ICD-10 K55.x)
Severe pain out of proportion
Acute coronary syndrome (ICD-10 I21.x)
Epigastric discomfort atypical presentation
Hepatobiliary and GI mimics
Mimics
Biliary colic (ICD-10 K80.20)
Episodic pain typically < 6 hours without fever
Choledocholithiasis (ICD-10 K80.50)
Cholestatic lab pattern and jaundice
Acute hepatitis (ICD-10 K75.9)
Marked AST ALT elevation
Peptic ulcer disease (ICD-10 K27.9)
Appendicitis high or retrocecal (ICD-10 K35.x)
Pulmonary and renal mimics
Extra-abdominal mimics
Right lower lobe pneumonia (ICD-10 J18.9)
Pulmonary embolism (ICD-10 I26.x)
Pyelonephritis or nephrolithiasis (ICD-10 N10 or N20.x)
Laboratory Tests
Core labs
Baseline evaluation
Complete blood count
Leukocytosis supports inflammation
Leukopenia possible in severe sepsis
Electrolytes and renal function
Creatinine for contrast and antibiotic dosing
Liver enzymes and cholestasis markers
ALT and AST
Alkaline phosphatase
GGT
Total bilirubin
Lipase
Pancreatitis evaluation and gallstone pancreatitis detection
Sepsis and organ dysfunction
Severity labs
Lactate
≥ 2 mmol/L perfusion abnormality marker
Blood cultures
If fever or sepsis physiology prior to antibiotics when feasible
Venous blood gas
pH and CO2 evaluation in shock
Coagulation studies
INR and aPTT for surgery planning or liver dysfunction
Special situation labs
Context-specific tests
Pregnancy test in patients with pregnancy potential
Altered imaging choice and antibiotic selection
Troponin if epigastric pain with cardiac risk or atypical symptoms
Glucose and ketones if diabetic with vomiting or dehydration
Interpretation pearls
Patterns
Mild AST ALT elevation possible in acute cholecystitis
Prominent bilirubin and alkaline phosphatase elevation suggests CBD obstruction
Marked AST ALT elevation suggests hepatitis or transient CBD obstruction
Diagnostic Tests
Scoring Systems
Severity and risk stratification
Tokyo Guidelines severity grading
Grade I mild
No organ dysfunction
Mild local inflammation
Grade II moderate
Marked local inflammation or difficult surgery predictors
Elevated WBC and symptoms > 72 hours support higher severity
Grade III severe
Organ dysfunction
Cardiovascular dysfunction requiring vasopressors
Neurologic dysfunction
Respiratory dysfunction
Renal dysfunction
Hepatic dysfunction
Hematologic dysfunction
Sepsis screening
qSOFA
SBP ≤ 100 mmHg
Respiratory rate ≥ 22 per minute
Altered mentation
MRI
MR imaging options
MRCP
Suspected choledocholithiasis with equivocal ultrasound
Pregnancy or contrast avoidance scenarios
Limitations
Time and availability constraints in unstable patients
Motion artifact with severe pain or vomiting
CT
CT abdomen pelvis
Indications
Alternative diagnosis evaluation when ultrasound nondiagnostic
Complicated disease concern
Perforation
Abscess
Emphysematous cholecystitis
Typical findings
Gallbladder distension
Wall thickening
Pericholecystic fluid
Pericholecystic fat stranding
Contrast considerations
Renal dysfunction risk mitigation
Ultrasound (or US)
First-line imaging
RUQ ultrasound features
Gallstones
Shadowing echogenic foci
Sonographic Murphy sign
Gallbladder wall thickening
Typically > 3 mm supports inflammation
Pericholecystic fluid
Gallbladder distension
Common bile duct diameter
Dilatation supports CBD obstruction
POCUS applications
Rapid detection of cholelithiasis and wall thickening
Shock workup adjunct
Free fluid evaluation
Cardiac function and IVC assessment
Second-line confirmatory test
HIDA scan
Nonvisualization of gallbladder supports cystic duct obstruction
Use when ultrasound equivocal and clinical suspicion persists
Disposition
Level of care
Admission decisions
Inpatient admission typical for acute cholecystitis
IV antibiotics requirement
Surgical planning requirement
ICU indications
Vasopressor requirement
Persistent lactate elevation despite fluids
Respiratory failure
Multi-organ dysfunction
Operative pathway
Surgical management pathway
Early laparoscopic cholecystectomy preferred when feasible
Within 72 hours of symptom onset when possible
Nonoperative bridge options
Percutaneous cholecystostomy for poor surgical candidates
Interval cholecystectomy planning after stabilization
Discharge criteria
Rare outpatient pathway criteria
Symptoms resolved with ED therapy
No fever
No leukocytosis trend upward
No imaging evidence of acute cholecystitis
Reliable follow-up within 24-72 hours
Treatment
Supportive care
Initial management bundle
NPO status
Oral intake reintroduction after symptom control and plan established
IV fluids
Balanced crystalloid bolus 10-20 mL/kg if hypovolemia
Reassessment after each bolus
Antiemetic therapy
Ondansetron IV 4 mg
Repeat every 6-8 hours as needed
Metoclopramide IV 10 mg
Avoid in QT prolongation when possible
Analgesia
Pain control
NSAID first-line when not contraindicated
Ketorolac IV 15 mg
Repeat every 6 hours as needed
Maximum 60 mg per day
Avoid in eGFR < 30 mL/min/1.73 m2
Opioid for refractory pain
Morphine IV 0.05 mg/kg
Repeat every 10-20 minutes to effect
Hydromorphone IV 0.2 mg
Repeat every 10-20 minutes to effect
Adjunct acetaminophen
Acetaminophen PO or IV 1000 mg
Maximum 3000 mg per day in older adults or liver disease risk
Antibiotics
Empiric antimicrobial therapy
Indications
Suspected acute cholecystitis
Systemic inflammation or fever
Complicated disease concern
Community-acquired mild to moderate
Ceftriaxone IV 2 g daily
Plus metronidazole IV 500 mg every 8 hours
Ampicillin-sulbactam IV 3 g every 6 hours
Avoid if local resistance high
Community-acquired severe or sepsis
Piperacillin-tazobactam IV 4.5 g every 6 hours
Renal dose adjustment with reduced eGFR
Cefepime IV 2 g every 8-12 hours
Plus metronidazole IV 500 mg every 8 hours
Healthcare-associated or ESBL risk
Meropenem IV 1 g every 8 hours
Renal dose adjustment
Severe beta-lactam allergy
Ciprofloxacin IV 400 mg every 12 hours
Plus metronidazole IV 500 mg every 8 hours
Aztreonam IV 2 g every 8 hours
Plus metronidazole IV 500 mg every 8 hours
Duration principles
Uncomplicated with source control, discontinue within 24 hours post-cholecystectomy
No source control or complicated infection, 4-7 days based on response
Source control and procedures
Definitive therapy
Early laparoscopic cholecystectomy
Class I recommendation in operable patients based on guideline consensus
Reduced length of stay compared with delayed surgery
Percutaneous cholecystostomy
If high operative risk or unstable physiology
Bridge to interval cholecystectomy
ERCP
If cholangitis or persistent CBD obstruction suspected
If gallstone pancreatitis with ongoing obstruction
Escalation for complications
Complication management
If emphysematous cholecystitis suspected
Immediate broad-spectrum antibiotics
Emergent surgical source control
If perforation or abscess
CT-guided drainage consideration
Surgical exploration based on stability and imaging
Special Populations
Pregnancy
Pregnancy considerations
Diagnosis and imaging
RUQ ultrasound preferred first-line
MRCP preferred for CBD evaluation when needed
Medication safety
Avoid NSAIDs in third trimester when possible
Ceftriaxone and metronidazole generally acceptable when indicated
Operative timing
Laparoscopic cholecystectomy feasible in all trimesters when clinically indicated
Obstetric consultation for fetal monitoring planning
Geriatric
Older adult considerations
Atypical presentation
Minimal fever or localized tenderness possible
Delirium as presenting feature
Higher complication risk
Emphysematous cholecystitis risk increased with diabetes and age
Medication adjustments
Reduced opioid starting doses
Renal-based antibiotic and NSAID caution
Pediatrics
Pediatric considerations
Etiologies beyond gallstones
Hemolytic disease
Obesity-related gallstones
Total parenteral nutrition association
Imaging
RUQ ultrasound first-line
Weight-based therapy
Ceftriaxone IV 50 mg/kg daily
Maximum 2 g per day
Metronidazole IV 10 mg/kg every 8 hours
Maximum 500 mg per dose
Background
Epidemiology
Epidemiology facts
Most common cause is gallstone obstruction of cystic duct
Cholelithiasis prevalence increases with age and female sex
Acalculous cholecystitis minority of cases
Higher morbidity and mortality
Typical in critical illness or prolonged fasting
Pathophysiology
Mechanism
Cystic duct obstruction
Gallbladder distension
Mucosal ischemia
Secondary bacterial infection potential
Local inflammatory cascade
Wall edema and thickening
Pericholecystic fluid
Complications
Gangrenous change
Perforation and abscess
Emphysematous infection with gas-forming organisms
Therapeutic Considerations
Treatment rationale
Source control is definitive therapy
Early cholecystectomy reduces recurrence and ongoing inflammation
Antibiotics are adjunct to source control
Target enteric Gram-negative and anaerobes when indicated
Pain control and hydration reduce physiologic stress
Avoid over-resuscitation in cardiac or renal disease
Patient Discharge Instructions
copy discharge instructions
Discharge guidance
Diagnosis summary
Biliary pain or gallbladder inflammation evaluation completed
Home care
Clear fluids and low-fat meals until follow-up
Hydration with frequent small sips
Acetaminophen as directed for pain
Medications
If antibiotics prescribed, complete full course
Avoid alcohol with metronidazole if prescribed
Follow-up
Surgery or clinic follow-up within 24-72 hours if suspected gallbladder inflammation
Planned elective cholecystectomy discussion if gallstones confirmed
Return to ED immediately
Worsening abdominal pain
Persistent vomiting or inability to keep fluids down
Fever or shaking chills
Yellow skin or eyes
Dark urine or pale stools
Fainting or severe weakness
New confusion
References
Clinical guidelines and society statements
Guideline sources
Tokyo Guidelines for acute cholecystitis and cholangitis severity grading and management
Severity grading framework widely used for Grade I to III stratification
World Society of Emergency Surgery guidance on acute calculous cholecystitis management
Early laparoscopic cholecystectomy as preferred definitive therapy in suitable candidates
Evidence-based sources
Core evidence
Randomized trials and meta-analyses comparing early versus delayed laparoscopic cholecystectomy
Early surgery associated with shorter hospital length of stay
Imaging literature supporting RUQ ultrasound as first-line test for suspected acute cholecystitis
HIDA scan utility when ultrasound is equivocal and suspicion remains
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.